NEVVI Medicare utilization intelligence
or

← back

Provider profile

DIDWANIA, VISHAL M.D.

Infectious Disease · NPI 1760619969 · BURR RIDGE, IL

1
Groups
21
Codes · 2024
39,267
Disclosed services

DIDWANIA, VISHAL is a Infectious Disease in BURR RIDGE, IL, a member of 1 medical group, who billed 21 distinct codes to Medicare Part B in 2024.

Groups: METRO INFECTIOUS DISEASE CONSULTANTS LLC (BURR RIDGE, IL)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

39,267
disclosed services
21
codes billed to Medicare Part B
Prior year · CY2023 45,728 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0878 Injection, daptomycin, 1 mg
J0875 Injection, dalbavancin, 5 mg
J1745 Injection, infliximab, excludes biosimilar, 10 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
J0696 Injection, ceftriaxone sodium, per 250 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
J1335 Injection, ertapenem sodium, 500 mg
96372 Injection of drug or substance under skin or into muscle
96413 Administration of chemotherapy into vein, 1 hour or less
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
36415 Insertion of needle into vein for collection of blood sample
99442 Telephone medical discussion with physician, 11-20 minutes
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96415 Administration of chemotherapy into vein, each additional hour
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96375 Injection of additional new drug or substance into vein
99443 Telephone medical discussion with physician, 21-30 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.